Commentary

Video

Dr Secord on Mirvetuximab Soravtansine in Platinum-Sensitive, FRα-High Ovarian Cancer

Angeles A. Secord, MD, MHSc, discusses the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive, FRα-high ovarian cancer.

Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.

The single-arm, open-label trial evaluated mirvetuximab soravtansine at a dose of 6 mg/kg every 3 weeks in patients who had received at least 3 prior lines of therapy, including at least 2 platinum-containing regimens. Patients with BRCA-mutated disease were required to have received a prior PARP inhibitor, and prior exposure to bevacizumab (Avastin) was not required.

The trial’s primary end point of investigator-assessed overall response rate (ORR) in the overall population (n = 79) was 51.9% (95% CI, 40.4%-63.3%) and consisted of best overall responses of complete response (7.6%), partial response (44.3%), stable disease (36.7%), progressive disease (8.9%), and not evaluable (2.5%). The median duration of response (DOR), which was a key secondary end point, was 8.25 months (95% CI, 5.55-10.78). The median progression-free survival was 6.93 months (95% CI, 5.85-9.59).

Among patients with prior PARP inhibitor exposure (n = 64), the ORR was 46.9% (95% CI, 34.3%-59.8%), and the median DOR was 8.3 months (95% CI, 5.5-10.8). Among those who had progressed on prior PARP inhibitors (n = 59), the ORR was 45.8% (95% CI, 32.7%-59.2%), and the median DOR was 7.3 months (95% CI, 5.0-10.8). Among patients who were PARP inhibitor–naive (n = 12), the ORR was 75.0% (95% CI, 42.8%-94.5%), and the median DOR was 8.8 months (95% CI, 3.5-NR).

Testing patients for FRα expression level is crucial for clinical decision-making for patients with ovarian cancer, Secord says, as high FRα expression is a key biomarker of efficacy of several therapies for this disease. Knowing a patient’s FRα expression level also aids in determining optimal, personalized treatment sequencing, she concludes.

Related Videos
Kimmie Ng, MD, MPH
Marina Chiara Garassino, MD
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Rahul Banerjee, MD, FACP
Seth Wander, MD, PhD
Piotr Rutkowski, MD
Javier Martín Broto MD, PhD
Nicolas Girard, MD
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Guru P. Sonpavde, MD